Skip to main content
SpringerLink
Log in

Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma

  • Chapter
  • First Online:
Renal Cancer

  • 993 Accesses

Abstract

RCC remains the most lethal of genitourinary malignancies. It will be essential to rationally integrate surgery and systemic therapy to improve outcomes in RCC. Despite substantial efforts to date, there is no current role for adjuvant therapy following nephrectomy for clinically localized disease. There are several studies in progress that aim to identify effective agents in the adjuvant setting, including mTOR and tyrosine kinase inhibitors as well as a monoclonal antibody against CA IX. For locally advanced disease, it has been proposed that neoadjuvant therapy may make unresectable disease resectable, enable partial nephrectomy, or shrink venous tumor thrombus. These theoretical goals remain in need of further study. For patients with metastatic RCC, the correct paradigm remains to be elucidated for integrating cytoreductive surgery and systemic therapy. In particular, the proper criteria for selecting patients for surgery, the benefit of cytoreduction in the targeted therapy era, and the correct order of surgery and systemic therapy are all active areas of debate and research.

Disclosures: Pfizer (Investigator, Consultant, Speaker’s Bureau); Argos (Investigator, Consultant); GlaxoSmithKline (Investigator); Bayer (Investigator); Novartis (Investigator); Wilex (Investigator)

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. N H, Noone A, Kraphcho M, Neyman N, editors. SEER cancer statistics review, 1975–2008 [Internet]. 2011 [cited 2011 Dec. 7]; Available from: http://seer.cancer.gov/csr/1975_2008/.

  2. Bex A, Jonasch E, Kirkali Z, et al. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. Eur Urol. 2010;58(6):819–28.

    Article  PubMed  Google Scholar 

  3. Jacobsohn K, Wood C. Adjuvant therapy for renal cell carcinoma. Semin Oncol. 2006;33(5):576–82.

    Article  CAS  PubMed  Google Scholar 

  4. Wood CG. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome. Clin Cancer Res. 2007;13(2 Pt 2):697s–702.

    Article  PubMed  Google Scholar 

  5. Cindolo L, la Taille de A, Messina G, et al. A preoperative clinical prognostic model for non-metastatic renal cell carcinoma. BJU Int. 2003;92(9):901–5.

    Article  CAS  PubMed  Google Scholar 

  6. Yaycioglu O, Roberts WW, Chan T, Epstein JI, Marshall FF, Kavoussi LR. Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model. Urology. 2001;58(2):141–5.

    Article  CAS  PubMed  Google Scholar 

  7. Raj GV, Thompson RH, Leibovich BC, Blute ML, Russo P, Kattan MW. Preoperative nomogram predicting 12-year probability of metastatic renal cancer. J Urol. 2008;179(6):2146–51. discussion2151.

    Article  PubMed  Google Scholar 

  8. Smaldone MC, Fung C, Uzzo RG, Haas NB. Adjuvant and neoadjuvant therapies in high-risk renal cell carcinoma. Hematol Oncol Clin North Am. 2011;25(4):765–91.

    Article  PubMed  Google Scholar 

  9. Lane BR, Kattan MW. Prognostic models and algorithms in renal cell carcinoma. Urol Clin North Am. 2008;35(4):613–25. vii.

    Article  PubMed  Google Scholar 

  10. Cindolo L, Patard J-J, Chiodini P, et al. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer. 2005;104(7):1362–71.

    Article  PubMed  Google Scholar 

  11. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol. 2001;166(1):63–7.

    Article  CAS  PubMed  Google Scholar 

  12. Sorbellini M, Kattan MW, Snyder ME, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol. 2005;173(1):48–51.

    Article  PubMed  Google Scholar 

  13. Leibovich BC, Blute ML, CHEVILLE JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;97(7):1663–71.

    Article  PubMed  Google Scholar 

  14. Zisman A. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002;20(23):4559–66.

    Article  PubMed  Google Scholar 

  15. Kenney PA, Wood CG. Integration of surgery and systemic therapy for renal cell carcinoma. Urol Clin North Am. 2012;39(2):211–31. vii.

    Article  PubMed  Google Scholar 

  16. Crispen PL, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED. Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers. Cancer. 2008;113(3):450–60.

    Article  PubMed  Google Scholar 

  17. Levy DA, Slaton JW, Swanson DA, Dinney CP. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol. 1998;159(4):1163–7.

    Article  CAS  PubMed  Google Scholar 

  18. Klatte T, Lam JS, Shuch B, Belldegrun AS, Pantuck AJ. Surveillance for renal cell carcinoma: why and how? When and how often? Urol Oncol Semin Orig Inv. 2008;26(5):550–4.

    Article  Google Scholar 

  19. Patard JJ. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol. 2004;22(16):3316–22.

    Article  PubMed  Google Scholar 

  20. Kim HL. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res. 2004;10(16):5464–71.

    Article  CAS  PubMed  Google Scholar 

  21. Klatte T, Seligson DB, LaRochelle J, et al. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol Biomarkers Prev. 2009;18(3):894–900.

    Article  CAS  PubMed  Google Scholar 

  22. Parker AS, Leibovich BC, Lohse CM, et al. Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer. 2009;115(10):2092–103.

    Article  PubMed  Google Scholar 

  23. Choueiri M, Tannir N, Jonasch E. Adjuvant and neoadjuvant therapy in renal cell carcinoma. Curr Clin Pharmacol. 2011;6(3):144–50.

    Article  CAS  PubMed  Google Scholar 

  24. Aref I, Bociek RG, Salhani D. Is post-operative radiation for renal cell carcinoma justified? Radiother Oncol. 1997;43(2):155–7.

    Article  CAS  PubMed  Google Scholar 

  25. Finney R. The value of radiotherapy in the treatment of hypernephroma-a clinical trial. BJU Int. 1973;45(3):258–69.

    Article  CAS  Google Scholar 

  26. Kjaer M, Frederiksen P. Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen renal cancer study group. Int J Radiat Oncol Biol Phys. 1987;13(5):665–72.

    Article  CAS  PubMed  Google Scholar 

  27. Lam JS, Belldegrun AS, Figlin RA. Adjuvant treatment for renal cell carcinoma. Expert Opin Pharmacother. 2006;7(6):706–20.

    Article  Google Scholar 

  28. Pizzocaro G, Piva L, Di Fronzo G, et al. Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study. J Urol. 1987;138(6):1379–81.

    CAS  PubMed  Google Scholar 

  29. Fujikawa K, Matsui Y, Miura K, et al. Serum immunosuppressive acidic protein and natural killer cell activity in patients with metastatic renal cell carcinoma before and after nephrectomy. J Urol. 2000;164(3 Pt 1):673–5.

    CAS  PubMed  Google Scholar 

  30. Dadian G, Riches PG, Henderson DC, et al. Immunological parameters in peripheral blood of patients with renal cell carcinoma before and after nephrectomy. Br J Urol. 1994;74(1):15–22.

    Article  CAS  PubMed  Google Scholar 

  31. Montie JE, Straffon RA, Deodhar SD, Barna B. In vitro assessment of cell-mediated immunity in patients with renal cell carcinoma. J Urol. 1976;115(3):239–42.

    CAS  PubMed  Google Scholar 

  32. Rayman P. Effect of renal cell carcinomas on the development of type 1 T-cell responses. Clin Cancer Res. 2004;10(18):6360S–6.

    Article  CAS  PubMed  Google Scholar 

  33. Arya M, Chao D, Patel HRH. Allogeneic hematopoietic stem-cell transplantation: the next generation of therapy for metastatic renal cell cancer. Nat Clin Pract Oncol. 2004;1(1):32–8.

    Article  PubMed  Google Scholar 

  34. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23(1):133–41.

    Article  CAS  PubMed  Google Scholar 

  35. Lam J, Leppert J, Belldegrun A. Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol. 2005;23(3):202–12.

    Article  CAS  PubMed  Google Scholar 

  36. Shimabukuro T, Naito K. Tumor-infiltrating lymphocytes derived from human renal cell carcinoma: clonal analysis of its characteristics. Int J Urol. 2008;15(3):241–4.

    Article  PubMed  Google Scholar 

  37. Kradin R, Lazarus D, Dubinett S, et al. Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet. 1989;333(8638):577–80.

    Article  Google Scholar 

  38. Finke J, Tubbs R, Connelly B, Pontes E, Montie J. Tumor-infiltrating lymphocytes in patients with renal-cell carcinoma. Ann NY Acad Sci. 1988;532:387–94. 1 Cytotoxic T C.

    Article  CAS  PubMed  Google Scholar 

  39. Vogelzang NJ, Priest ER, Borden L. Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup. J Urol. 1992;148(4):1247–8.

    CAS  PubMed  Google Scholar 

  40. Sánchez-Ortiz RF, Tannir N, Ahrar K, Wood CG. Spontaneous regression of pulmonary metastases from renal cell carcinoma after radio frequency ablation of primary tumor: an in situ tumor vaccine? J Urol. 2003;170(1):178–9.

    Article  PubMed  Google Scholar 

  41. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical research council renal cancer collaborators. Lancet 1999;353(9146):14–7.

    Google Scholar 

  42. Pyrhönen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol. 1999;17(9):2859–67.

    PubMed  Google Scholar 

  43. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13(3):688–96.

    CAS  PubMed  Google Scholar 

  44. Messing EM, Manola J, Wilding G, et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern cooperative oncology group/intergroup trial. J Clin Oncol. 2003;21(7):1214–22.

    Article  CAS  PubMed  Google Scholar 

  45. Pizzocaro G, Piva L, Colavita M, et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol. 2001;19(2):425–31.

    CAS  PubMed  Google Scholar 

  46. Clark JI, Atkins MB, Urba WJ, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol. 2003;21(16):3133–40.

    Article  CAS  PubMed  Google Scholar 

  47. Atzpodien J, Schmitt E, Gertenbach U, et al. Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer. 2005;92(5):843–6.

    Article  CAS  PubMed  Google Scholar 

  48. Galligioni E, Quaia M, Merlo A, et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: five-year results of a prospective randomized study. Cancer. 1996;77(12):2560–6.

    Article  CAS  PubMed  Google Scholar 

  49. Jocham D, Richter A, Hoffmann L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet. 2004;363(9409):594–9.

    Article  CAS  PubMed  Google Scholar 

  50. Rassweiler J. Re: ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. Eur Urol. 2012;61(1):219–20.

    Article  PubMed  Google Scholar 

  51. Doehn C, Richter A, Theodor RA, Lehmacher W, Jocham D. An adjuvant vaccination with Reniale prolongs survival in patients with renal cell carcinoma following radical nephrectomy [Internet]. Eur. Urol. Suppl. 2006 [cited 2011 Dec. 7];5:286. Available from: http://www.sciencedirect.com/science/article/pii/S0302283811011201.

  52. May M, Brookman-May S, Hoschke B, et al. Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. Cancer Immunol Immunother. 2010;59(5):687–95.

    Article  PubMed  Google Scholar 

  53. Wood C, Srivastava P, Bukowski R, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet. 2008;372(9633):145–54.

    Article  CAS  PubMed  Google Scholar 

  54. Margulis V, Matin SF, Tannir N, et al. Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma. Urology. 2009;73(2):337–41.

    Article  PubMed  Google Scholar 

  55. Daliani DD, Papandreou CN, Thall PF, et al. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer. 2002;95(4):758–65.

    Article  CAS  PubMed  Google Scholar 

  56. Kjaer M, Iversen P, Hvidt V, et al. A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. A study by the Copenhagen Renal Cancer Study Group. Scand J Urol Nephrol. 1987;21(4):285–9.

    Article  CAS  PubMed  Google Scholar 

  57. Bex A, Horenblas S, Meinhardt W, Verra N, de Gast GC. The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ. Eur Urol. 2002;42(6):570–4. discussion575–6.

    Article  CAS  PubMed  Google Scholar 

  58. Jonasch E, Tannir NM. Targeted therapy for locally advanced renal cell carcinoma. Target Oncol. 2010;5(2):113–8.

    Article  PubMed  Google Scholar 

  59. Kalman D, Varenhorst E. The role of arterial embolization in renal cell carcinoma. Scand J Urol Nephrol. 1999;33(3):162–70.

    Article  CAS  PubMed  Google Scholar 

  60. Mohr SJ, Whitesel JA. Spontaneous regression of renal cell carcinoma metastases after preoperative embolization of primary tumor and subsequent nephrectomy. Urology. 1979;14(1):5–8.

    Article  CAS  PubMed  Google Scholar 

  61. Swanson DA, Johnson DE, von Eschenbach AC, Chuang VP, Wallace S. Angioinfarction plus nephrectomy for metastatic renal cell carcinoma–an update. J Urol. 1983;130(3):449–52.

    CAS  PubMed  Google Scholar 

  62. Bakke A, Göthlin JH, Haukaas SA, Kalland T. Augmentation of natural killer cell activity after arterial embolization of renal carcinomas. Cancer Res. 1982;42(9):3880–3.

    CAS  PubMed  Google Scholar 

  63. Nakano H, Nihira H, Toge T. Treatment of renal cancer patients by transcatheter embolization and its effects on lymphocyte proliferative responses. J Urol. 1983;130(1):24–7.

    CAS  PubMed  Google Scholar 

  64. Johnson G, Kalland T. Enhancement of mouse natural killer cell activity after dearterialization of experimental renal tumors. J Urol. 1984;132(6):1250–3.

    CAS  PubMed  Google Scholar 

  65. Zielinski H, Szmigielski S, Petrovich Z. Comparison of preoperative embolization followed by radical nephrectomy with radical nephrectomy alone for renal cell carcinoma. Am J Clin Oncol. 2000;23(1):6–12.

    Article  CAS  PubMed  Google Scholar 

  66. Abel EJ, Culp SH, Tannir NM, et al. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol. 2011;59(1):10–5.

    Article  PubMed  Google Scholar 

  67. Robert G, Gabbay G, Bram R, et al. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma. Eur Urol. 2009;55(6):1477–80.

    Article  CAS  PubMed  Google Scholar 

  68. Van der Veldt AAM, Meijerink MR, van den Eertwegh AJM, et al. Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res. 2008;14(8):2431–6.

    Article  PubMed  Google Scholar 

  69. Desar IME, van Herpen CML, van Laarhoven HWM, Barentsz JO, Oyen WJG, van der Graaf WTA. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev. 2009;35(4):309–21.

    Article  CAS  PubMed  Google Scholar 

  70. Thomas AA, Rini BI, Lane BR, et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol. 2009;181(2):518–23. discussion523.

    Article  CAS  PubMed  Google Scholar 

  71. Jonasch E, Wood CG, Matin SF, et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(25):4076–81.

    Article  CAS  PubMed  Google Scholar 

  72. Cowey CL, Amin C, Pruthi RS, et al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol. 2010;28(9):1502–7.

    Article  CAS  PubMed  Google Scholar 

  73. Ficarra V, Novara G. Kidney cancer: neoadjuvant targeted therapies in renal cell carcinoma. Nat Rev Urol. 2010;7(2):63–4.

    Article  CAS  PubMed  Google Scholar 

  74. Rini BI, Garcia J, Elson P, et al. The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery. J Urol. 2012;187(5):1548–54.

    Article  CAS  PubMed  Google Scholar 

  75. Lau WK, Blute ML, Weaver AL, Torres VE, Zincke H. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc. 2000;75(12):1236–42.

    Article  CAS  PubMed  Google Scholar 

  76. McKiernan J, Simmons R, Katz J, Russo P. Natural history of chronic renal insufficiency after partial and radical nephrectomy. Urology. 2002;59(6):816–20.

    Article  PubMed  Google Scholar 

  77. Huang WC, Elkin EB, Levey AS, Jang TL, Russo P. Partial nephrectomy versus radical nephrectomy in patients with small renal tumors--is there a difference in mortality and cardiovascular outcomes? J Urol. 2009;181(1):55–61. discussion61–2.

    Article  PubMed  Google Scholar 

  78. Tan H-J, Norton EC, Ye Z, Hafez KS, Gore JL, Miller DC. Long-term survival following partial vs radical nephrectomy among older patients with early-stage kidney cancer. JAMA. 2012;307(15):1629–35.

    Article  CAS  PubMed  Google Scholar 

  79. van Poppel H, Da Pozzo L, Albrecht W, et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2011;59(4):543–52.

    Article  PubMed  Google Scholar 

  80. Hellenthal NJ, Underwood W, Penetrante R, et al. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol. 2010;184(3):859–64.

    Article  CAS  PubMed  Google Scholar 

  81. Ansari J, Doherty A, McCafferty I, Wallace M, Deshmukh N, Porfiri E. Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma. Clin Genitourin Cancer. 2009;7(2):E39–41.

    Article  PubMed  Google Scholar 

  82. Thomas AA, Rini BI, Stephenson AJ, et al. Surgical resection of renal cell carcinoma after targeted therapy. J Urol. 2009;182(3):881–6.

    Article  PubMed  Google Scholar 

  83. Silberstein JL, Millard F, Mehrazin R, et al. Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery. BJU Int. 2010;106(9):1270–6.

    Article  PubMed  Google Scholar 

  84. Simmons MN, Ching CB, Samplaski MK, Park CH, Gill IS. Kidney tumor location measurement using the C index method. J Urol. 2010;183(5):1708–13.

    Article  PubMed  Google Scholar 

  85. Kutikov A, Uzzo RG. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol. 2009;182(3):844–53.

    Article  PubMed  Google Scholar 

  86. Karakiewicz PI, Suardi N, Jeldres C, et al. Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol. 2008;53(4):845–8.

    Article  PubMed  Google Scholar 

  87. Harshman LC, Srinivas S, Kamaya A, Chung BI. Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib. Nat Rev Urol. 2009;6(6):338–43.

    Article  PubMed  Google Scholar 

  88. Bex A, Van der Veldt AAM, Blank C, Meijerink MR, Boven E, Haanen JBAG. Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib. Acta Oncol. 2010;49(4):520–3.

    Article  CAS  PubMed  Google Scholar 

  89. Cost NG, Delacroix SE Jr, Sleeper JP, et al. The Impact of Targeted Molecular Therapies on the Level of Renal Cell Carcinoma Vena Caval Tumor Thrombus. Eur Urol. 2011;59(6):912–918. DOI: 10.1016/j.eururo.2011.02.032.

    Google Scholar 

  90. Flanigan RC. Debulking nephrectomy in metastatic renal cancer. Clin Cancer Res. 2004;10(18 Pt 2):6335S–41.

    Article  PubMed  Google Scholar 

  91. Mani S, Todd MB, Katz K, Poo WJ. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol. 1995;154(1):35–40.

    Article  CAS  PubMed  Google Scholar 

  92. Fisher R, Coltman C. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med. 1988;108(4):518–23.

    Article  CAS  PubMed  Google Scholar 

  93. Muss H, Costanzi J, Leavitt R. Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration. J Clin Oncol. 1987;5:286–91.

    CAS  PubMed  Google Scholar 

  94. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol. 2000;163(2):408–17.

    Article  CAS  PubMed  Google Scholar 

  95. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8):2530–40.

    CAS  PubMed  Google Scholar 

  96. Flanigan R, Salmon S. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655–9.

    Article  CAS  PubMed  Google Scholar 

  97. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. European Organisation for Research and Treatment of Cancer (EORTC) genitourinary group. radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358(9286):966–70.

    Article  CAS  PubMed  Google Scholar 

  98. Flanigan RC, Mickisch G, Sylvester R, Tangen C, van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004;171(3):1071–6.

    Article  PubMed  Google Scholar 

  99. Pantuck AJ, Zisman A, Dorey F, et al. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer. 2003;97(12):2995–3002.

    Article  PubMed  Google Scholar 

  100. Vasselli JR, Yang JC, Linehan WM, White DE, Rosenberg SA, Walther MM. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol. 2001;166(1):68–72.

    Article  CAS  PubMed  Google Scholar 

  101. Han K-R, Pantuck AJ, Bui MHT, et al. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology. 2003;61(2):314–319. ISSN 0090-4295, 10.1016/S0090-4295(02)02163–5. http://www.sciencedirect.com/science/article/pii/S0090429502021635.

  102. Slaton J, Perrotte P, Balbay M, Levy D. Reassessment of the selection criteria for cytoreductive nephrectomy in patients with metastatic renal cell carcinoma. J Urol. 2000;163 Suppl 4:70.

    Google Scholar 

  103. Wood C, Huber N, Madsen L, Fortner C. Clinical variables that predict survival following cytoreductive nephrectomy for metastatic renal cell carcinoma. J Urol. 2001;165(5 Suppl):184A.

    Google Scholar 

  104. Culp SH, Tannir NM, Abel EJ, et al. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer. 2010;116(14):3378–88.

    Article  PubMed  Google Scholar 

  105. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–81.

    Article  CAS  PubMed  Google Scholar 

  106. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24.

    Article  CAS  PubMed  Google Scholar 

  107. Escudier B, Eisen T, Stadler W. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–34.

    Article  CAS  PubMed  Google Scholar 

  108. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449–56.

    Article  CAS  PubMed  Google Scholar 

  109. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26(33):5422–8.

    Article  CAS  PubMed  Google Scholar 

  110. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103–11.

    Article  PubMed  Google Scholar 

  111. Szczylik C, Porta C, Bracarda S, et al. Sunitinib in patients with or without prior nephrectomy (Nx) in an expanded access trial of metastatic renal cell ­carcinoma (mRCC). J Clin Oncol. [Internet] 2008;26(15 suppl.):abstr5124. Available from: http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/5124?sid=ee6c06b3-e9fb-4158-a5e5-54d5bddbfe40.

  112. Choueiri TK, Xie W, Kollmannsberger C, et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol. 2011;185(1):60–6.

    Article  PubMed  Google Scholar 

  113. Warren M, Venner PM, North S, et al. A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell ­carcinoma in Alberta and the role of nephrectomy prior to treatment. Can Urol Assoc J. 2009;3(4):281–9.

    PubMed  Google Scholar 

  114. Singer EA, Srinivasan R, Bratslavsky G. Editorial comment. J Urol. 2011;185(1):66.

    Article  PubMed  Google Scholar 

  115. Margulis V, Wood CG. Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider presurgical systemic therapy? Eur Urol. 2008;54(3):489–92.

    Article  PubMed  Google Scholar 

  116. Margulis V, Wood CG, Jonasch E, Matin SF. Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors. Curr Oncol Rep. 2008;10(3):253–8.

    Article  CAS  PubMed  Google Scholar 

  117. Bex A, Van der Veldt AAM, Blank C, et al. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J Urol. 2009;27(4):533–9.

    Article  CAS  PubMed  Google Scholar 

  118. Lara PN, Tangen CM, Conlon SJ, Flanigan RC, Crawford ED, Southwest Oncology Group Trial S8949. Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949. J Urol. 2009;181(2):512–6. discussion516–7.

    Article  PubMed  Google Scholar 

  119. Rodríguez Faba O, Breda A, Rosales A, et al. Neoadjuvant temsirolimus effectiveness in downstaging advanced non–clear cell renal cell carcinoma. Eur Urol. 2010;58(2):307–10.

    Article  PubMed  Google Scholar 

  120. Shuch B, Riggs SB, LaRochelle JC, et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int. 2008;102(6):692–6.

    Article  PubMed  Google Scholar 

  121. Amin C, Wallen E, Pruthi RS, Calvo BF, Godley PA, Rathmell WK. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology. 2008;72(4):864–8.

    Article  PubMed  Google Scholar 

  122. Wood CG, Margulis V. Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease. Cancer. 2009;115(10 Suppl):2355–60.

    Article  PubMed  Google Scholar 

  123. Patard J-J, Thuret R, Raffi A, Laguerre B, Bensalah K, Culine S. Treatment with sunitinib enabled complete resection of massive lymphadenopathy not ­previously amenable to excision in a patient with renal cell carcinoma. Eur Urol. 2009;55(1):237–9. quiz239.

    Article  PubMed  Google Scholar 

  124. Powles T, Kayani I, Blank C, et al. The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. Ann Oncol. 2011;22(5):1041–7.

    Article  CAS  PubMed  Google Scholar 

  125. Plimack ER, Tannir N, Lin E, Bekele BN, Jonasch E. Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures. Cancer. 2009;115(9):1859–66.

    Article  CAS  PubMed  Google Scholar 

  126. Ebos JML, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15(3):232–9.

    Article  CAS  PubMed  Google Scholar 

  127. Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15(3):220–31.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, MD Anderson Cancer Center, 1515 Holcombe Blvd - Unit 1373, 77030, Houston, TX, USA

    Patrick A. Kenney M.D. & Christopher G. Wood M.D. FACS

Authors
  1. Patrick A. Kenney M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher G. Wood M.D. FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick A. Kenney M.D. .

Editor information

Editors and Affiliations

  1. , Institute of Urology, Lahey Clinic, 41 Mall Road, Burlington, 01805, Massachusetts, USA

    John A Libertino

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Kenney, P.A., Wood, C.G. (2013). Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma. In: Libertino, J. (eds) Renal Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-7236-0_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-7236-0_10

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-7235-3

  • Online ISBN: 978-1-4614-7236-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation